Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 58,790 shares, a decrease of 18.2% from the February 26th total of 71,837 shares. Currently, 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 15,085 shares, the days-to-cover ratio is presently 3.9 days.

Analyst Upgrades and Downgrades

XCUR has been the topic of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. Wall Street Zen raised Exicure to a “hold” rating in a report on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Exicure Stock Performance

Shares of Exicure stock opened at $4.41 on Monday. The stock has a market cap of $28.09 million, a P/E ratio of -5.73 and a beta of 4.13. The stock’s fifty day moving average is $4.34 and its 200 day moving average is $4.67. Exicure has a one year low of $3.10 and a one year high of $14.11.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($18.60) by $18.14.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.